<DOC>
	<DOCNO>NCT02423577</DOCNO>
	<brief_summary>The purpose study determine effect FF-3 comparison placebo subject experimentally inoculated live , challenge strain influenza A virus .</brief_summary>
	<brief_title>Safety Protective Efficacy FF-3 Dry Powder Healthy Subjects Infected With Influenza Challenge Strain</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<criteria>1 . Healthy male nonpregnant , nonlactating female subject 18 50 year age inclusive 2 . Body Mass Index ( BMI ) 18 32 kg/m2 inclusive body weight 50 110 kg inclusive . 3 . Normal spirometry value Screening Baseline 4 . Postmenopausal woman amenorrhea least 2 year eligible 5 . Females childbearing potential must use two acceptable birth control method throughout study 30 day last dose IMP : 6 . Male subject : Must agree use condom ( diaphragm ) plus spermicide female partner ) time first dose IMP 90 day last dose . Must agree donate sperm 90 day last dose IMP . Documented evidence vasectomy males 180 day minimum prior first dose IMP acceptable form contraception . Males claim abstinence method contraception allow provided agree use double barrier method ( diaphragm plus spermicide female partner condom ) become sexually active screen 90 day last dose IMP . 7 . Willing able provide write informed consent . 8 . Willing able adhere lifestyle guideline restriction outline protocol Subjects may enrol study follow exclusion criterion fulfil : 1 . Evidence history clinically significant oncologic , pulmonary , hepatic , gastrointestinal , cardiovascular , hematologic , metabolic , neurological , immunologic , nephrologic , endocrine , psychiatric disease . 2 . Current infection nature unless agree insignificant study Investigator Medical Monitor . 3 . Nasal abnormality , include nasal septum deviation , septum perforation , polyp ; history recurrent epistaxis ; history sinus surgery and/or persistent hypertrophic inferior turbinate . 4 . Significant abnormality screen safety laboratory test , ECGs , spirometry . 5 . Bronchoreactive airway disease ( asthma , chronic obstructive pulmonary disease , current allergic rhinitis , cystic fibrosis , chronic bronchitis , emphysema ) . Individuals history childhood asthma necessarily exclude acceptable screening . 6 . History significant nasal irritation use nasal spray drop . 7 . History drug alcohol abuse within past 2 year 8 . Nicotine product user 9 . Received investigational drug participate another research study within 90 day first dose IMP . 10 . Participated previous investigational study FF3 . 11 . History influenza vaccination live attenuate vaccine within previous year 12 . Use prescription drug within 14 day prior first dose IMP , except oral contraceptive . 13 . Received nonprescription medication , vitamin , dietary supplement within 14 day administration first dose IMP , unless Principal Investigator Medical Monitor grant prior approval . Herbal supplement must discontinue 7 day prior first dose IMP . 15 . Tested positive alcohol screen admission CRU . 16 . Positive urine pregnancy test Screening Visit positive serum pregnancy test admission CRU ( female ) . 17 . Positive test HIV , hepatitis B surface antigen ( HBsAg ) antihepatitis C virus ( antiHCV ) screen visit . 18 . Positive urine drug test screen visit admission CRU . 19 . Likelihood require treatment study period drug permit study protocol . 20 . Subjects donate blood experienced significant blood loss within 56 day screen study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>antiviral</keyword>
	<keyword>influenza</keyword>
	<keyword>challenge</keyword>
</DOC>